{"name":"Repare Therapeutics","slug":"repare-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":115941000,"netIncome":-84689000,"cash":176506000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Olaparib 200-300 mg BID, daily","genericName":"Olaparib 200-300 mg BID, daily","slug":"olaparib-200-300-mg-bid-daily","indication":"Relapsed/refractory metastatic breast cancer (in combination with vorinostat)","status":"discontinued"}]}],"pipeline":[{"name":"Olaparib 200-300 mg BID, daily","genericName":"Olaparib 200-300 mg BID, daily","slug":"olaparib-200-300-mg-bid-daily","phase":"discontinued","mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers.","indications":["Relapsed/refractory metastatic breast cancer (in combination with vorinostat)","BRCA-mutant breast cancer (in combination with sapacitabine)","Advanced solid tumors (RP-3467 + olaparib combination)","High-grade serous ovarian cancer (idetrexed + olaparib)","Small-cell lung cancer (olaparib + low-dose radiotherapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPT0djX3ozMU5NMnBGRFJKemZIeUlFbEQ1Y1JabWFUZXhGVkI1Mk1yMjJrOUU3SzJSeDZYSlRXdTEwaF91d0MzZ0VNelZhbldRVFlaQ3MyeUdKYTlzd1NvdVpoYzlaZDhyd0Z5clZ5emlYN2ZBZ0R6UFdadDFhY2ZiMm10YUxVd1AwUVEtQW5fTjJ4QnJuTXNPUGdsME5fVmNpeHFVOFh3UTJQaXVzQU96cVBISURFaEsyaUhwYXdkYlk?oc=5","date":"2026-02-01","type":"pipeline","source":"AD HOC NEWS","summary":"Repare Therapeutics (RPTX) Just Exploded: Is This Tiny Cancer Stock Your Next Huge Win or a Total Tr - AD HOC NEWS","headline":"Repare Therapeutics (RPTX) Just Exploded: Is This Tiny Cancer Stock Your Next Huge Win or a Total Tr","sentiment":"neutral"},{"date":"2026-01-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc0cyOGhHNTVycFFxZXhNaVNzRXJMV25wWWZWVUh3UFUzeFZPc2hXTkRyWm1PNF9jQ3UyMlNsOEVoLXk0TGV4YlJSUXQyMkFSbDJaNXZwTFVGSHpWZGtUOUpDWUNsMDhod3huUVlicndjYnlKYmdmODZ4TGJFX2lSVFhMdEZFV2VPQm5OdWVPNDVoc1ZackZmRnd1czJ3MENydkR4QmlMNGYwcGFkSXg4NmEycUxaTkpNdEhwU3FzZzhURjQ?oc=5","date":"2026-01-05","type":"pipeline","source":"AD HOC NEWS","summary":"Repare Therapeutics (RPTX) Is Exploding: Is This Biotech Underdog a Secret Goldmine or Total Trap? - AD HOC NEWS","headline":"Repare Therapeutics (RPTX) Is Exploding: Is This Biotech Underdog a Secret Goldmine or Total Trap?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQOFpob2NiV3FMbm54YlpRTVdkNHoybGtFWlF5cHo1RW5WVFdIMm54eUhGQWtuSVUzalVPY2VieXVnRjdkRDhuYk50NmtwMFRkRVd5QUZDdzV2bXhXTWtteklfRUNkSGc3eEpRQkljckxhY216cTdGYXp4bUVPZ1BGRFAtSDZnazhya3ZTdGlxTFZDdjB1VjNoVm1OTQ?oc=5","date":"2026-01-02","type":"deal","source":"Fierce Biotech","summary":"AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals - Fierce Biotech","headline":"AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNODRqUnAyM3k5TnY0aHc0MmhWZC1PT2lQU2NWbnppZk1fdi14dm5WRmY0bkdMRkkyYzRxNFR5bTVPWDBSeXB0dzJNOWlnZ3V2RWZyMjBKNERCNFZ3QnZhNGNwX0ZKMS1SQ3JvYUFHOEg3YjdIX3FVdDF4Q1FqbUdCbUYtYk9Ydw?oc=5","date":"2025-12-26","type":"deal","source":"Pharmaceutical Technology","summary":"Gilead Sciences to acquire Repare’s RP-3467 - Pharmaceutical Technology","headline":"Gilead Sciences to acquire Repare’s RP-3467","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNbWFhOXZxVm5pUjhoZFI4bkEwcVk2UTN0TU1MVGkwUFB2RzE1R0tBU0N0eW9FY3ViTVk5aXdRdUpQcTl1My1HdUhwMEtTLTJfb25pYk1kUFJzYWxrZDg3UDhHSHlOa2o3aFJIMXV6dGNadzI1clI2WHdIYkM1cExCS0VFRFpNenNpMUhKUzBub1o0Z1JsQ2IweA?oc=5","date":"2025-11-17","type":"deal","source":"Fierce Biotech","summary":"Repare finds fix as biotech agrees to XenoTherapeutics buyout - Fierce Biotech","headline":"Repare finds fix as biotech agrees to XenoTherapeutics buyout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOT2EyZ1JfVEl6Q0E4YVltM1RHVUpWNXc3bFZQcUlZRHd0RDlDcWNwMWJTZkF1ZV91U09LWjhXTnVqQ3JXdzZHOXpmdzlweG9UQmRnNU5DbWh2U1NpajZDdHRXRWpaUFZCTXFJWkUwMlhSZVQyeFRob0QyU0hxTUpDNkhad0NLTVk0NlA1RVdvNTh6WEJua0tZQ3Vydml2QnJfZUg1QS1pd19PVVpk?oc=5","date":"2025-07-16","type":"deal","source":"Fierce Biotech","summary":"Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm - Fierce Biotech","headline":"Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBsTDM3c0hqUy1xTFFOMWlyUnBJU19yNlR3cllfTjI4U3pfN1laV1ZTOWZwbTRnLWhVcEM3LUZPenpCN0NvZ1paeDgxZy1oZnQ0VUJB?oc=5","date":"2025-07-15","type":"deal","source":"FirstWord Pharma","summary":"Debiopharm bags rights to Repare's PKMYT1 inhibitor in $267M deal - FirstWord Pharma","headline":"Debiopharm bags rights to Repare's PKMYT1 inhibitor in $267M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNTjZGNEtXNVFxV0FucWNPSUlNMTF5XzNGZWctT2ZGMWpwT25XMURfLU1TcmRTc0s1eXNQQUdVOVRfaXppcVg3YV8wYzE1ZVZVY2toUElYakNMSHB5cXhsVTNzeGhCYVM0ckFybG1IbjRJTUtHazVHQ3BPQ0tTM0U2S0NtYzJrdGxDN1RoRQ?oc=5","date":"2025-05-12","type":"pipeline","source":"The ASCO Post","summary":"In Case You Missed It: Additional Abstracts of Interest From AACR - The ASCO Post","headline":"In Case You Missed It: Additional Abstracts of Interest From AACR","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-01","type":"deal","source":"businesswire.com","summary":"Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - bu","headline":"Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare The","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-04-29","type":"pipeline","source":"simplywall.st","summary":"Is Repare Therapeutics (NASDAQ:RPTX) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Repare Therapeutics (NASDAQ:RPTX) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1YMG9CMnpXd0VESEJVS0EyZzVKdFdHb0NMZ3h6RUgycVNDMlI3YmoxTFg2cDBMekJvQThiLV8talY4ak8zNlN1WGhSdmN0NDB1eDdKVFlFQlMxVElHdXA5bGlzNy1UY0pLU2xOcmE5aHpETXFwbTJKQ191OA?oc=5","date":"2024-08-29","type":"trial","source":"Oncology Pipeline","summary":"Repare shelves its early work | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Repare shelves its early work | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNaHc5YVVEd09JY0JvdnMyR1VJeDVBLVVTVGdmZ1Q4dzRBRTBodzYwRGF6RldPaXgtSVhveEwwd2c5c0REcDFybF90RlFlU080SVZiSzRkN3hzYnF4a1RsTjNzcER1T1d1ckJCank0ZjRFcEJHaWljVjZTRExDcUxWb2xHRFRVbW5QYUg4TFFSbTRhZWZWckhKeWkwcGZkb0psQ3NEVmVMaEc4cUNwSVlhRGxtUQ?oc=5","date":"2024-02-13","type":"pipeline","source":"Pharmaceutical Executive","summary":"Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib - Pharmaceutical Executive","headline":"Roche Ends Agreement With Repare Therapeutics to Develop ATR Inhibitor Camonsertib","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":115941000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-84689000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":176506000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}